Monopar Therapeutics Inc. (MNPR:NASDAQ) closed at $70.47 on October 26, 2026, down 0.26% on the day. The stock trades 43.5% below its 52-week high of $124.82 and 40.7% above its 52-week low of $50.07. Over the past year, it lost 13.4%. Monopar Therapeutics Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, MNPR closed higher on 121 days (48%). Its best day was June 23, 2026 (+19.09%) and its worst was February 4, 2026 (-11.15%). The stock moved 10% or more in a single session 8 times.
Monopar Therapeutics Inc is the United States-based clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. Its pipeline products comprise of Validive, Camsirubicin, and MNPR-101.
Find more stocks like MNPR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.